DCF Advisers LLC Boosts Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

DCF Advisers LLC grew its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 162.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,400 shares of the company's stock after buying an additional 55,400 shares during the period. NewAmsterdam Pharma accounts for approximately 1.1% of DCF Advisers LLC's holdings, making the stock its 28th biggest position. DCF Advisers LLC owned 0.10% of NewAmsterdam Pharma worth $2,298,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. FMR LLC grew its holdings in NewAmsterdam Pharma by 35.6% in the third quarter. FMR LLC now owns 330,412 shares of the company's stock worth $5,485,000 after purchasing an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock worth $3,972,000 after acquiring an additional 221,305 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after purchasing an additional 14,280 shares in the last quarter. State Street Corp grew its position in NewAmsterdam Pharma by 168.7% during the 3rd quarter. State Street Corp now owns 37,915 shares of the company's stock valued at $629,000 after purchasing an additional 23,805 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after purchasing an additional 1,399 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NAMS. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, Needham & Company LLC dropped their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $43.33.

Insider Activity

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $25.54, for a total transaction of $762,266.84. Following the transaction, the insider now owns 10,656,172 shares of the company's stock, valued at $272,158,632.88. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 213,284 shares of company stock valued at $4,687,489 in the last ninety days. Corporate insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.59 during trading on Tuesday, hitting $23.41. The company's stock had a trading volume of 1,070,865 shares, compared to its average volume of 513,234. The company has a 50-day moving average of $21.75 and a 200-day moving average of $21.10. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -9.00 and a beta of -0.04. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. As a group, research analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.